MDR1 haplotypes derived from exons 21 and 26 do not affect the steady‐state pharmacokinetics of tacrolimus in renal transplant patients
Open Access
- 3 September 2004
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (5), 548-553
- https://doi.org/10.1111/j.1365-2125.2004.02182.x
Abstract
Aim This retrospective study investigated the influence of MDR1 haplotypes derived from the polymorphisms 2677G > T (exon 21) and 3435C > T (exon 26) on the pharmacokinetics of the immunosuppressant drug tacrolimus in 73 renal transplant patients. Methods Based on both variants of SNPs 2677 and 3435, four different haplotypes and eight different genotypes were identified in the study sample. Tacrolimus trough concentrations (C0) were compared between different SNP variants and genotypes, as well as between carriers and noncarriers of each haplotype. Additionally, CYP3A5 genotype (6956G > A) was determined. Results No significant differences were observed between groups. Differences in mean tacrolimus C0 values between carriers and noncarriers of each haplotype ranged from −0.04 µg/litre (95% confidence interval: −0.53 to 0.60) to −23 µg/litre (−1.07 to 1.53). No association was found between CYP3A5*1/*3 genotype and tacrolimus Co concentractions. Conclusion MDR1 haplotypes derived from the SNPs 2677G > T (exon 21) and 3435C > T (exon 26) do not influence the pharmacokinetics of tacrolimus in renal transplant patients.This publication has 28 references indexed in Scilit:
- MDR1 Haplotypes Modify BEN Disease Risk: A Study in Bulgarian Patients with Balkan Endemic Nephropathy Compared to Healthy ControlsNephron Experimental Nephrology, 2004
- Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2Transplantation, 2003
- Tacrolimus—Clarithromycin Interaction in a Patient Receiving Bone Marrow TransplantationAnnals of Pharmacotherapy, 2002
- Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirementTransplantation, 2002
- The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patientsLiver Transplantation, 2002
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depressionThe Pharmacogenomics Journal, 2002
- Mechanisms of Clinically Relevant Drug Interactions Associated with TacrolimusClinical Pharmacokinetics, 2002
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences of the United States of America, 2000
- Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proceedings of the National Academy of Sciences of the United States of America, 1989